Cardiovascular remodeling and metabolic disorders in patiens with comorbidity of essential hypertension and type 2 diabetes depending on genetic polymorphism PPARγ2

Abstract

The aim of the study: to investigate Pro12Ala PPARγ2 polymorphism and its association with the severity of vascular remodeling and metabolic disorders in comorbidity of essential hypertension (EH) and type 2 diabetes (DM2) in Ukrainian population. The main group of our study consisted of 287 patients with EH in combination with DM2. The group of comparison consisted of 68 patients with EH without DM2. The control group consisted of 25 healthy individuals. It was determined that in all study groups the dominating factor belonged to the patients with Pro allele in the absence of significant differences between the groups. The patients with Pro12Ala/Ala12Ala genotype have significantly lower values of intima-media thickness and pulse wave velocity in the carotid artery, lower levels of malondialdehyde and diene conjugates and significantly higher degree of endothelium-dependent vasodilation, higher levels of superoxide dismutase and catalase than in genotype Pro/Pro. It was determined that metabolic disorders were less pronounced in patients with genotype Pro12Ala/Ala12Ala. Conclusions: The genetic polymorphism PPARγ2 affected the severity of heart remodeling and vascular atherosclerotic processes with comorbidity of EH and DM2. Pro12Ala/Ala12Ala genotype can be considered as a protective polymorphism at specified comorbidity.